Remacemide
Based on 1 Customer Validation
Remacemide (FPL 12924) is an orally active, non-competitive, low-affinity NMDA receptor antagonist. Remacemide shows neuroprotection activity in animal models of hypoxia and ischemic stroke. Remacemide is also an anticonvulsant, and can be used in Parkinson's disease and Huntington's disease research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 128298-28-2
- 分子式: C17H20N2O
- 分子量:268.35
-
保管条件:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
iGluR アイソフォーム固有の製品をすべて表示
More
生物活性
|
NMDA Receptor |
化学情報
-
CAS 番号 128298-28-2
-
性状 Solid
-
分子量 268.35
-
分子式 C17H20N2O
-
SMILES
O=C(CN)NC(C)(CC1=CC=CC=C1)C2=CC=CC=C2
-
別名
FPL 12924; PR 934-423; FPL 13592
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
DMSO : 87.5 mg/mL (326.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (271 KB)
-
SDS (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Schachter SC, et al. Remacemide: current status and clinical applications. Expert Opin Investig Drugs. 2000 Apr;9(4):871-83. [Content Brief]
[2]. Dyker AG, et al. Remacemide hydrochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke. Stroke. 1999 Sep;30(9):1796-801. [Content Brief]
[3]. Greenamyre JT, et al. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neurol. 1994 Jun;35(6):655-61. [Content Brief]
[4]. Kieburtz K, et al. A controlled trial of remacemide hydrochloride in Huntington's disease. Mov Disord. 1996 May;11(3):273-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7265 mL | 18.6324 mL | 37.2648 mL | 93.1619 mL |
| 5 mM | 0.7453 mL | 3.7265 mL | 7.4530 mL | 18.6324 mL | |
| 10 mM | 0.3726 mL | 1.8632 mL | 3.7265 mL | 9.3162 mL | |
| 15 mM | 0.2484 mL | 1.2422 mL | 2.4843 mL | 6.2108 mL | |
| 20 mM | 0.1863 mL | 0.9316 mL | 1.8632 mL | 4.6581 mL | |
| 25 mM | 0.1491 mL | 0.7453 mL | 1.4906 mL | 3.7265 mL | |
| 30 mM | 0.1242 mL | 0.6211 mL | 1.2422 mL | 3.1054 mL | |
| 40 mM | 0.0932 mL | 0.4658 mL | 0.9316 mL | 2.3290 mL | |
| 50 mM | 0.0745 mL | 0.3726 mL | 0.7453 mL | 1.8632 mL | |
| 60 mM | 0.0621 mL | 0.3105 mL | 0.6211 mL | 1.5527 mL | |
| 80 mM | 0.0466 mL | 0.2329 mL | 0.4658 mL | 1.1645 mL | |
| 100 mM | 0.0373 mL | 0.1863 mL | 0.3726 mL | 0.9316 mL |